scispace - formally typeset
J

Jinqian Liu

Researcher at Amgen

Publications -  25
Citations -  990

Jinqian Liu is an academic researcher from Amgen. The author has contributed to research in topics: Chemistry & Agonist. The author has an hindex of 14, co-authored 21 publications receiving 926 citations.

Papers
More filters
Journal ArticleDOI

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

TL;DR: High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4.
Journal ArticleDOI

AMG 837: a potent, orally bioavailable GPR40 agonist.

TL;DR: Optimize of a series of β-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.
Journal ArticleDOI

SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase

TL;DR: Novel non-nucleoside inhibitors of the HCV RNA polymerase (NS5b) with sub-micromolar biochemical potency have been identified which are selective for the inhibition of HCV NS5b over other polymerases.
Patent

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

TL;DR: In this article, the authors present compounds useful for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided.
Journal ArticleDOI

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

TL;DR: The optimization from the G PR40 partial agonist 1 to the structurally and pharmacologically distinct GPR40 full agonist AM-1638 (21) is presented and the improved in vivo efficacy that GPR 40 full agonists 21 exhibits in BDF/DIO mice as compared to partial agonists 1.